US Stock MarketDetailed Quotes
PRLD Prelude Therapeutics
- 3.790
- -0.080-2.07%
Trading May 31 13:52 ET
208.18MMarket Cap-2037P/E (TTM)
3.940High3.594Low47.56KVolume3.840Open3.870Pre Close179.08KTurnover0.35%Turnover RatioLossP/E (Static)54.93MShares6.02552wk High0.99P/B51.71MFloat Cap1.66052wk Low--Dividend TTM13.64MShs Float95.375Historical High--Div YieldTTM8.94%Amplitude1.660Historical Low3.765Avg Price1Lot Size
Prelude Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -5.50%-31.79M | -27.87%-107.06M | -2.84%-23.58M | -25.66%-25.68M | -49.82%-27.67M | -37.63%-30.13M | -0.24%-83.73M | 10.80%-22.93M | 6.13%-20.44M | 7.25%-18.47M |
| Net income from continuing operations | -13.40%-31.43M | -5.54%-121.83M | -15.48%-33.08M | -2.17%-30.61M | -11.17%-30.43M | 5.93%-27.72M | -3.35%-115.44M | 12.79%-28.64M | 2.38%-29.96M | -1.89%-27.37M |
| Depreciation and amortization | 53.24%426K | -11.71%1.17M | -8.56%331K | -17.21%279K | -11.64%281K | -9.45%278K | 44.70%1.32M | 24.83%362K | 26.69%337K | 59.80%318K |
| Other non cash items | -4.17%414K | 12.69%1.94M | 39.13%608K | 3.42%454K | 2.55%442K | 5.11%432K | 29.37%1.72M | 9.25%437K | 23.31%439K | 48.62%431K |
| Change In working capital | 41.74%-5.21M | -1,224.36%-10.48M | 594.94%3.72M | -170.42%-926K | -496.52%-4.33M | -1,132.55%-8.94M | -74.29%932K | -125.53%-751K | 45.79%1.32M | -50.92%1.09M |
| -Change in prepaid assets | 88.69%-788K | -136.98%-9.11M | -2,699.21%-7.05M | 109.46%487K | 202.25%4.43M | -7,589.25%-6.97M | -178.08%-3.84M | -121.91%-252K | -43.96%-5.15M | 417.31%1.46M |
| -Change in payables and accrued expense | -231.00%-5.06M | -96.11%252K | 5,879.41%3.93M | -68.86%2.15M | -7,773.21%-4.3M | -283.21%-1.53M | 1.89%6.49M | 93.67%-68K | 38.77%6.9M | -97.50%56K |
| -Change in other current liabilities | 245.48%643K | 5.08%-1.62M | 38.05%-267K | -6.68%-463K | -5.85%-452K | -5.49%-442K | -25.90%-1.71M | -5.64%-431K | 11.79%-434K | -43.29%-427K |
| -Change in other working capital | ---- | ---- | ---- | ---3.1M | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -5.50%-31.79M | -27.87%-107.06M | -2.84%-23.58M | -25.66%-25.68M | -49.82%-27.67M | -37.63%-30.13M | -0.24%-83.73M | 10.80%-22.93M | 6.13%-20.44M | 7.25%-18.47M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 73.46%31.22M | -142.41%-34.65M | 470.92%7.74M | -30.37%15.05M | -539.01%-75.43M | -56.68%18M | 130.97%81.69M | 175.11%1.36M | 108.29%21.61M | 4,609.45%17.18M |
| Net PPE purchase and sale | 64.32%-289K | -16.36%-3.51M | -187.28%-1.13M | 35.48%-591K | -29.68%-983K | 14.92%-810K | -29.96%-3.02M | -32.32%-393K | -39.00%-916K | -98.95%-758K |
| Net investment purchase and sale | 67.53%31.51M | -136.75%-31.13M | 407.15%8.87M | -30.58%15.64M | -514.98%-74.44M | -55.74%18.81M | 132.40%84.71M | 215.99%1.75M | 108.66%22.52M | --17.94M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 73.46%31.22M | -142.41%-34.65M | 470.92%7.74M | -30.37%15.05M | -539.01%-75.43M | -56.68%18M | 130.97%81.69M | 175.11%1.36M | 108.29%21.61M | 4,609.45%17.18M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 94.80%-14K | 16,635.58%136.4M | 16,181.94%25.24M | -40.54%88K | 30,913.65%111.34M | -275.82%-269K | -99.51%815K | -92.07%155K | -79.18%148K | -14.93%359K |
| Net common stock issuance | ---- | --135.73M | --24.94M | --104K | ---- | ---- | --0 | --0 | --0 | ---- |
| Proceeds from stock option exercised by employees | -92.86%2K | -16.44%681K | 94.84%302K | --0 | -2.23%351K | -81.70%28K | -78.42%815K | -93.13%155K | -79.18%148K | -14.93%359K |
| Net other financing activities | 94.61%-16K | ---17K | ---1K | ---- | ---- | ---297K | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 94.80%-14K | 16,635.58%136.4M | 16,181.94%25.24M | -40.54%88K | 30,913.65%111.34M | -275.82%-269K | -99.51%815K | -92.07%155K | -79.18%148K | -14.93%359K |
| Net cash flow | ||||||||||
| Beginning cash position | -15.34%29.34M | -3.41%34.65M | -64.43%19.94M | -44.31%30.49M | -60.05%22.25M | -3.41%34.65M | -83.57%35.87M | -8.72%56.07M | -84.04%54.75M | -84.66%55.68M |
| Current changes in cash | 95.29%-584K | -334.51%-5.31M | 143.87%9.4M | -901.67%-10.55M | 988.47%8.25M | -162.63%-12.4M | 99.33%-1.22M | 16.18%-21.42M | 100.47%1.32M | 95.33%-928K |
| End cash Position | 29.25%28.75M | -15.34%29.34M | -15.34%29.34M | -64.43%19.94M | -44.31%30.49M | -60.05%22.25M | -3.41%34.65M | -3.41%34.65M | -8.72%56.07M | -84.04%54.75M |
| Free cash flow | -3.67%-32.08M | -27.47%-110.58M | -5.95%-24.71M | -23.03%-26.27M | -49.02%-28.65M | -35.44%-30.94M | -1.04%-86.75M | 10.30%-23.32M | 4.81%-21.36M | 5.26%-19.23M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
